Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy AstraZeneca PLC ADR stock

Learn how to easily invest in AstraZeneca PLC ADR stock.

AstraZeneca PLC ADR (AZN) is a leading drug manufacturers-general business based in the US. It opened the day at $64.15 after a previous close of $66.07. During the day the price has varied from a low of $64.07 to a high of $65.97. The latest price was $65.95 (25 minute delay). AstraZeneca PLC ADR is listed on the NASDAQ and employs 83,100 staff. All prices are listed in US Dollars.

How to buy shares in AstraZeneca PLC ADR

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AZN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

How has coronavirus impacted AstraZeneca PLC ADR's share price?

Since the stock market crash in March caused by coronavirus, AstraZeneca PLC ADR's share price has had significant positive movement.

Its last close price was $65.95, which is 23.93% up on its pre-crash value of $50.17 and 82.43% up on the lowest point reached during the March crash when the shares fell as low as $36.15.

If you had bought $1,000 worth of AstraZeneca PLC ADR shares at the start of February 2020, those shares would have been worth $799.26 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1.00.

In mid-November 2021, AstraZeneca announced that its COVID-19 vaccine, which was developed in partnership with the University of Oxford, has an average efficacy of 70%. In some clinical tests, the vaccine was 90% effective. The company says it shipped over 2 billion doses of the vaccine available as of December, 2021.

The company’s vaccine follows news that Moderna and Pfizer have each developed vaccines. Shares of AstraZeneca (AZN) were down following the news.

AstraZeneca PLC ADR stock price (NASDAQ: AZN)

Use our graph to track the performance of AZN stocks over time.

AstraZeneca PLC ADR shares at a glance

Information last updated 2022-07-01.
Previous close$66.07
Change $-0.12
Change % -0.1816%
Volume 8,850,093
Information last updated 2022-07-03.
52-week range$52.76 - $71.70
50-day moving average $64.77
200-day moving average $61.30
Wall St. target price$71.80
PE ratio N/A
Dividend yield $2.87 (2.17%)
Earnings per share (TTM) $-0.36

Buy AstraZeneca PLC ADR shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 5 of 5
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy AstraZeneca PLC ADR stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

AstraZeneca PLC ADR price performance over time

Historical closes compared with the close of $65.95 from 2022-07-01

1 week (2022-06-27) -0.84%
1 month (2022-06-03) 0.38%
3 months (2022-04-04) -1.08%
6 months (2022-01-04) 15.16%
1 year (2021-07-02) 8.49%
2 years (2020-07-02) 22.58%
3 years (2019-07-03) 57.06%
5 years (2017-07-03) 94.66%

Is AstraZeneca PLC ADR stock undervalued or overvalued?

Valuing AstraZeneca PLC ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of AstraZeneca PLC ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

AstraZeneca PLC ADR's PEG ratio

AstraZeneca PLC ADR's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.4649. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into AstraZeneca PLC ADR's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

AstraZeneca PLC ADR's EBITDA

AstraZeneca PLC ADR's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $10.7 billion.

The EBITDA is a measure of a AstraZeneca PLC ADR's overall financial performance and is widely used to measure a its profitability.

AstraZeneca PLC ADR financials

Revenue TTM $41.5 billion
Operating margin TTM 15.15%
Gross profit TTM $27.6 billion
Return on assets TTM 4.76%
Return on equity TTM -4.17%
Profit margin -2.56%
Book value $11.74
Market capitalisation $204.4 billion

TTM: trailing 12 months

AstraZeneca PLC ADR share dividends


Dividend payout ratio: 51.62% of net profits

Recently AstraZeneca PLC ADR has paid out, on average, around 51.62% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.17% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), AstraZeneca PLC ADR shareholders could enjoy a 2.17% return on their shares, in the form of dividend payments. In AstraZeneca PLC ADR's case, that would currently equate to about $2.87 per share.

AstraZeneca PLC ADR's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.

AstraZeneca PLC ADR's most recent dividend payout was on 27 March 2022. The latest dividend was paid out to all shareholders who bought their shares by 23 February 2022 (the "ex-dividend date").

Have AstraZeneca PLC ADR's shares ever split?

AstraZeneca PLC ADR's shares were split on a 2:1 basis on 26 July 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your AstraZeneca PLC ADR shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for AstraZeneca PLC ADR shares which in turn could have impacted AstraZeneca PLC ADR's share price.

AstraZeneca PLC ADR share price volatility

Over the last 12 months, AstraZeneca PLC ADR's shares have ranged in value from as little as $52.7574 up to $71.7. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while AstraZeneca PLC ADR's is 0.1224. This would suggest that AstraZeneca PLC ADR's shares are less volatile than average (for this exchange).

AstraZeneca PLC ADR overview

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc.

Frequently asked questions

What percentage of AstraZeneca PLC ADR is owned by insiders or institutions?
Currently 0.059% of AstraZeneca PLC ADR shares are held by insiders and 17.834% by institutions.
How many people work for AstraZeneca PLC ADR?
Latest data suggests 83,100 work at AstraZeneca PLC ADR.
When does the fiscal year end for AstraZeneca PLC ADR?
AstraZeneca PLC ADR's fiscal year ends in December.
Where is AstraZeneca PLC ADR based?
AstraZeneca PLC ADR's address is: 1 Francis Crick Avenue, Cambridge, United Kingdom, CB2 0AA
What is AstraZeneca PLC ADR's ISIN number?
AstraZeneca PLC ADR's international securities identification number is: US0463531089
What is AstraZeneca PLC ADR's CUSIP number?
AstraZeneca PLC ADR's Committee on Uniform Securities Identification Procedures number is: 046353108

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site